#### Form 603

Corporations Act 2001 Section 671B

# Notice of initial substantial holder

To Company Name/ Scheme	CRESO PHARMA LIMITED
ACN/ ARSN	609 406 911
Details of substantial holder (1)  Name	L1 Capital Global Opportunites Master Fund
ACN/ ARSN (if applicable)	
The holder became a substantial holder on	24/02/2020

#### 2. Details of voting power

The total number of votes attached to all the voting shares in the company or voting interests in the scheme that the substantial holder or an associate (2) had a relevant interest (3) in on the date the substantial holder became a substantial holder are as follows:

Class of securities (4)	Number of securities	Person's votes (5)	Voting power (6)
FPO	11,390,976	11,390,976	5.48%

\*Based on issued capital of 207,809,368 shares

#### 3. Details of relevant interests

The nature of the relevant interest the substantial holder or an associate had in the following voting securities on the date the substantial holder became a substantial holder are as follows:

Holder of relevant interest	Nature of relevant interest (7)	Class and number of securities
See Schedule 1	, ,	

### 4. Details of present registered holders

The persons registered as holders of the securities referred to in paragraph 3 above are as follows:

Holder of relevant interest	Registered Holder of securities	Person entitled to be registered as holder (8)	Class and number of securities
See Schedule 1			

#### 5. Consideration

The consideration paid for each relevant interest referred to in paragraph 3 above, and acquired in the four months prior to the day that the substantial holder became a substantial holder is as follows:

Holder of relevant interest	Date of	Consideration (9)			
	acquisition	Cash	Non-cash	Class and number of securities	

603 page 2/2 15 July 2001

# 6. Associates

Name and ACN/ ARSN (if applicable)	Nature of association
N/A	

# 7. Addresses

(9)

was acquired.

The addresses of persons named in this form are as follows:

Name	Address
L1 Capital Global Opportunites Master Fund	161a Shedden Road. One Artillery Court. Grand Cayman, Cayman Islands

Signature						
	Print name	Da	avid Feldman	Capacity	Director	
	Sign here			Date	06/03/2020	
				DIRECTIONS		
(1)	trust), the names of	could be included in an	annexure to the form. If t	he relevant interests of a group	tion and its related corporations, or the mana of persons are essentially similar, they may l as of members is clearly set out in paragraph	be referred to throughout the
(2)	See the definition of	of "associate" in sectio	on 9 of the Corporations Ad	ct 2001.		
(3)	See the definition of	of "relevant interest" in	sections 608 and 671B(7	) of the Corporations Act 2001.		
(4)	The voting shares	of a company constitu	ite one class unless divide	ed into separate classes.		
(5)	The total number of	of votes attached to all	I the voting shares in the c	ompany or voting interests in th	e scheme (if any) that the person or an asso	ociate has a relevant
(6)	The person's votes	s divided by the total v	otes in the body corporate	or scheme multiplied by 100.		
(7)		setting out the terms	of any relevant agreement	, and a statement by the persor	vas acquired. If subsection 671B(4) applies, n giving full and accurate details of any contr rract, scheme or arrangement; and	
	(b)					
					r influence the exercise of, the voting powers securities to which the qualification applies).	
	See the definition of	of "relevant agreemen	t" in section 9 of the Corpo	orations Act 2001.		
(8)	If the substantial h	older is unable to dete	ermine the identity of the pe	erson ( eg. if the relevant interes	st arises because of an option) write "unknow	wn".

Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest

# Schedule 1 - L1 Capital Global Opportunities Master Fund becoming a substantial holder in CRESO PHARMA LIMITED **Details of relevant interests**

Holder of relevant interest	Nature of relevant interest	Class and number of securities	
	Power to (or to control) exercise vote and/or dispose of the securities as discretionary investment managers or advisers of superannuation funds, pooled superannuation trusts, managed investment schemes and investment management agreements.		11,390,976

# **Details of present registered holders**

Holder of relevant interest	Registered holder of securities	Persons entitled to be a registered holder	Class and number of securities
L1 Capital Global Opportunities Master Fund	Credit Suisse	Credit Suisse	11,390,976
		,	

11,390,976